SciVision Biotech expects its gross margin to reach a peak of nearly 70%, with a slight quarterly decrease and a significant yearly increase. The company will also have the opportunity to submit an application for a factory inspection and license in Brazil at the beginning of the second quarter. If the application is approved in Q4, it will open a door to the South American market.

According to SciVision, the most clear growth in demand in the first quarter was for its joint injection products, with Taiwan's market driven by the replacement of the three doses with one.

According to estimates, SciVision's current three-dosage form accounts for less than 20% of the company's revenue from domestic sales of joint injections, and in terms of volume, the proportion has dropped to around 40%.

In addition to Taiwan, SciVision also has new customers in Central and South America, such as Chile. In Brazil, the largest market, the company is also actively seeking GMP approval for the plant there, which is expected to be completed and submitted for approval in the beginning of the second quarter. In the European market, SciVision has already received test orders from customers in the Middle East during its recent visit to a exhibition.

As for aesthetics medicine, SciVision said that its Chinese customers are still under pressure to sell their inventories, and that shipments in the first quarter were at the same level as the previous quarter, but were better than during the Covid-19 lockdown.

In Indonesia, the Kalbe Group, a leading player in the country, has already obtained licenses for one and three injectable doses of joint cavity injections and subcutaneous fillers for beauty care.